Sep 17, 2024
AN OBSERVATIONAL STUDY ON THE EFFICACY OF DAPAGLIFLOZIN IN HEART FAILURE WITH REDUCED EJECTION FRACTION IN TERTIARY CARE HOSPITAL IN CENTRAL INDIA
- Meghna Bordoloi1,
- Shilpa Bawankule1,
- Sourya Acharya1,
- Sunil Kumar1
- 1Jawaharlal Nehru Medical College, Sawangi
Protocol Citation: Meghna Bordoloi, Shilpa Bawankule, Sourya Acharya, Sunil Kumar 2024. AN OBSERVATIONAL STUDY ON THE EFFICACY OF DAPAGLIFLOZIN IN HEART FAILURE WITH REDUCED EJECTION FRACTION IN TERTIARY CARE HOSPITAL IN CENTRAL INDIA. protocols.io https://dx.doi.org/10.17504/protocols.io.rm7vzjr18lx1/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: September 12, 2024
Last Modified: September 17, 2024
Protocol Integer ID: 107450
Keywords: Dapagliflozin, Heart failure, reduced ejection fraction, tertiary care hospital, central india
Abstract
Heart failure with reduced ejection fraction is a prevalent and debilitating condition associated with significant mortality and morbidity. Dapagliflozin, an SGLT2 inhibitor shows promising results in reducing cardiovascular events and improving clinical outcomes. However, Real world evidence of it’s efficacy and safety is limited. This observational study aims to study the effects of dapagliflozin in patients with heart failure with reduced ejection fraction. It expects to see reduced number of recurrent hospitalisation, cardiovascular deaths, improved NYHA class, and improvement in cardiometabolic parameters as well study the adverse effects that follows.
Attachments
Protocol references
1.Ponikowski P, Voors AA, Anker SD, et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016, 37:2129–200. 10.1093/eurheartj/ehw128
2.Yancy CW, Jessup M, Bozkurt B, et al.: 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017, 136:e137–61. 10.1161/CIR.0000000000000509
3.McMurray JJV, Solomon SD, Inzucchi SE, et al.: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019, 381:1995–2008. 10.1056/NEJMoa1911303
4.Hamad R, Penko J, Kazi DS, et al.: Association of Low Socioeconomic Status With Premature Coronary Heart Disease in US Adults. JAMA Cardiol. 2020, 5:899–908. 10.1001/jamacardio.2020.1458
5.Gupta M, Rao S, Manek G, Fonarow GC, Ghosh RK: The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence. Ther Clin Risk Manag. 2021, 17:823–30. 10.2147/TCRM.S275076
6.Palmiero G, Cesaro A, Vetrano E, et al.: Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. Int J Mol Sci. 2021, 22:5863. 10.3390/ijms22115863
7.Ali AE, Mazroua MS, ElSaban M, et al.: Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Global Heart. 2023, 18:. 10.5334/gh.1258
8.Fatima A, Rasool S, Devi S, et al.: Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management. Cureus. 15:e46243. 10.7759/cureus.46243